Cellectar, Inc
Cellectar Biosciences is dedicated to developing targeted cancer treatments using its innovative phospholipid ether (PLE) platform technology. The company focuses on designing and advancing drug candidates rapidly, with a pipeline that includes proprietary products like Iopofosine, and collaborates strategically to improve therapeutic outcomes for cancer patients worldwide.
Industries
Nr. of Employees
small (1-50)
Cellectar, Inc
100 Campus Drive, Suite 207, Florham Park, NJ 07932
Patents
Luminescent phospholipid analogs for the identification and isolation of circulating tumor cells
US-11467159-B2
View DetailsPhospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
US-9579406-B2
View Details
Luminescent phospholipid analogs for the identification and isolation of circulating tumor cells
US-11467159-B2
View DetailsPhospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
US-9579406-B2
View DetailsProducts
Iopofosine (CLR 131)
A small-molecule phospholipid ether-based radioconjugate labeled with iodine-131 designed for selective tumor cell uptake and intracellular radiation delivery; evaluated in multiple clinical studies and indications including Waldenstrom’s macroglobulinemia, multiple myeloma, and high-grade glioma.
CLR 1900 series
Internally developed series of phospholipid ether-conjugated small-molecule cytotoxics that target cell division pathways; currently in early preclinical development for solid tumors.
CLR 12120 series (alpha-emitting radioconjugates)
Alpha-emitting phospholipid ether radioconjugate program using actinium-225 payloads under development for treatment of refractory solid tumors.
CLR 125 (candidate for triple-negative breast cancer)
Product candidate advanced toward a Phase 1b clinical protocol submission to regulatory authorities for treatment of triple-negative breast cancer.
Iopofosine (CLR 131)
A small-molecule phospholipid ether-based radioconjugate labeled with iodine-131 designed for selective tumor cell uptake and intracellular radiation delivery; evaluated in multiple clinical studies and indications including Waldenstrom’s macroglobulinemia, multiple myeloma, and high-grade glioma.
CLR 1900 series
Internally developed series of phospholipid ether-conjugated small-molecule cytotoxics that target cell division pathways; currently in early preclinical development for solid tumors.
CLR 12120 series (alpha-emitting radioconjugates)
Alpha-emitting phospholipid ether radioconjugate program using actinium-225 payloads under development for treatment of refractory solid tumors.
CLR 125 (candidate for triple-negative breast cancer)
Product candidate advanced toward a Phase 1b clinical protocol submission to regulatory authorities for treatment of triple-negative breast cancer.
Services
Design and conduct of oncology trials including dose-finding, Phase 1, and pivotal expansion studies; management of trial sites and patient enrollment.
Joint development arrangements and licensing/co-development options to combine delivery platform expertise with external linkers, payloads, or commercialization capabilities.
Process and documentation support for academic groups seeking to collaborate on preclinical research using the delivery platform.
Policies and procedures to manage requests for expanded access to investigational therapeutics in clinical development.
Design and conduct of oncology trials including dose-finding, Phase 1, and pivotal expansion studies; management of trial sites and patient enrollment.
Joint development arrangements and licensing/co-development options to combine delivery platform expertise with external linkers, payloads, or commercialization capabilities.
Process and documentation support for academic groups seeking to collaborate on preclinical research using the delivery platform.
Policies and procedures to manage requests for expanded access to investigational therapeutics in clinical development.
Expertise Areas
- Targeted drug delivery
- Radiopharmaceutical development
- Conjugation and linker chemistry
- Preclinical pharmacology and animal models
Key Technologies
- Phospholipid ether-based targeting platform
- Radiolabeled small-molecule therapeutics
- Alpha-emitter therapeutics
- Linker-to-warhead conjugation chemistry
News & Updates
Scheduled for June 13, 2025, at 10:00am EDT.
Cellectar was granted FDA Breakthrough Therapy Designation for Iopofosine I 131 in treating Waldenstrom’s macroglobulinemia.
Scheduled for June 13, 2025, at 10:00am EDT.
Cellectar was granted FDA Breakthrough Therapy Designation for Iopofosine I 131 in treating Waldenstrom’s macroglobulinemia.